Israel R&D : Caesarea Business Park, P.O 4463 Caesarea Israel. U.S Office: #3 Bethesda Metro Center Suite 700 Bethesda, MD.
July 2015
2
Company overview
Cannabics Pharmaceuticals Inc. is engaged in the development and commercialization of personalized anticancer Cannabis based medicine. Cannabics focuses on the personalization of natural anticancer therapy. Utilizing throughput technology, we screen antitumor effects on biopsies treated with natural compounds. Since cannabis is known for its antitumor properties and has a great variance of active compounds, this in-vitro diagnostics process points out specific cannabis extracts with the potential of serving not only as a palliative treatment but also as an anticancer therapy. This technology enables the entourage of active ingredients found in diverse strains of cannabis to be harnessed in the fight against the diversity and sustainability of tumors.
Personalized anticancer medicine
There is a large cumulative and rapidly growing body of scientific data, which clearly indicates that cannabinoids specifically inhibit cancer cell growth and promote cancer cell death through apoptosis.
We have developed an automated high-throughput method for the screening of different types of cancer cells or biopsies treated with a
multitude of cannabis extracts. These natural extracts could also be tested in conjunction with approved synthetic drugs for patients that undergo chemotherapy for the most personally tailored therapy.
This multilayer method is producing a large-scale database that will capture the knowledge gained on to the unique effects of different combinations of cannabinoid compounds on diverse malignancies. Coextensive with the development of the automated high-throughput
3
system, we are also developing proprietary and novel compounds targeted on diverse types of tumors.
The advantages of Natural personalized Therapy
• Bio versatility- most drugs in the market are based on one active
molecule, which has a well-established effect on the biology of the patient but usually, has harsh side effects for the same reason. It is more likely to assume that a large variety of molecules would treat a highly varied disease as cancer with more efficacy.
• Personalized Medicine -PM is treating the individual rather than
groups of people. There are over 200 different known cancers and the genetic divergence among humans makes it nearly impossible to find one remedy for a group of people. PM is aiming to create a therapy for the biology of an individual by using personal biological data.
• Natural product- all natural compounds derived from the cannabis
plant are well known for their non-toxic nature while standard
chemotherapy is considered highly toxic with harsh side effects and in some cases cancerous itself.
Cannabics SR
As means of cannabis administration, Cannabics has developed a patent pending extended release formulation, distributed in Colorado as
WannaCaps XR and studied as a palliative treatment for cancer patients in a renowned medical center in Israel.
4
A patent pending extended release cannabis capsule
The Company’s marketed product is Cannabics SR, an extended release oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR 10mg delivers a steady level of beneficial effects for 6-8 hours. The once to twice per-day oral dosing regimen offered by Cannabics SR allows patients a more consistent beneficial effect without the dizziness and dissociation commonly found with immediate release administration methods or the inconvenience of frequent re-dosing. It also avoids the medical complications associated with smoking cannabis and the uneven dosage frequently encountered in other edibles.
Cannabics SR – Clinical Research and Development
On July 2014, the Company filed a non-provisional patent application with the U.S. Patent & Trademark Office and an international patent application with the Patent Cooperation Treaty division of the Israeli Patent Office, each covering the proprietary technology underlying Cannabics SR.
A clinical study in underway in the Oncology Department of the Rambam Medical Center will examine the effectiveness of Cannabics SR in
5
well as general improvement in quality of life and reduction of depression. We expect the first results to be available in September 2015.
You can find this study under “Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients” or from the NIH Clinical Trials website:
https://clinicaltrials.gov/ct2/show/study/NCT02359123 - contacts You can also see a more in-depth review at the (US) National Cancer Institute’s website:
http://www.cancer.gov/clinicaltrials/search/view?cdrid=769090&version=He althProfessional&protocolsearchid=12509449
We believe that clinical proof of safety and efficacy is of very high importance for the medical community and particularly to prescribing physicians. We anticipate that successful completion of our upcoming clinical studies with the Cannabics SR capsules will further legitimize the use of the capsules in the eyes of the medical community and will facilitate market penetration of Cannabics SR through coverage in publications by key opinion leaders in palliative oncology.
Cannabis SR in the U.S. market
In December 2014, the Company and Mountain High Products LLC, a Colorado corporation based in Boulder, Colorado, executed a Letter of Engagement contemplating the grant of a license to Mountain High for the exclusive production and distribution of Cannabics SR technology in the USA under the label Wanacaps XR.
6
Wanacaps XR
Three versions of Wanacaps XR are available in Colorado:
High THC Capsules—10 mg of THC, 1 mg of CBD.
THC/CBD Balanced Capsules --10 mg of THC and 10 mg of CBD.
High CBD Capsules —10 mg of CBD, 1 mg of THC.
In The news:
http://www.thedenverchannel.com/thenow/colorado-company-wana-brands-creates-first-ever-slow-release-cannabis-capsules
7
The Board
Dr. Eyal Ballan - Co-founder and CTO
Dr. Eyal Ballan is a co-founder of Cannabics Pharmaceuticals and serves as CTO. Dr. Ballan holds a Ph.D. in neurophysiology, EEG Brain wave analysis and attention. After his Ph.D. he was an entrepreneur in the field of biofeedback and developed a resonating neuro-feedback system. Dr. Ballan holds a M.Sc. in cancer research and was part of the research team who developed Salirasib (Treatment for Non-Small Cell Lung
Cancer). His expertise is in molecular biology, cell cultures and genomics and neurophysiology.
Mr. Itamar Borochov - Co-founder and CEO
Mr. Borochov is an environmentalist with vast experience as an
entrepreneur in the fields of organic agriculture and medical cannabis. For more than 15 years prior to his involvement with medical cannabis, Mr. Borochov was a real estate entrepreneur.
Mr. Shay Avraham Sarid - Co-founder
Mr. Sarid is a co-founder of Cannabics Inc. and he is also the founder of Seach, one of the oldest and largest medical Cannabis farms in Israel. Seach is an official supplier of medical grade Cannabis to the Israeli Ministry of Health and specifically licensed to grow and distribute medical cannabis to authorized patients. Shay is the recent Chairman of the Israeli Medical Cannabis Growers Council.
8
Mr. Dov Weinberg – Chief Financial Officer
Mr. Weinberg has over 30 years of broad experience in corporate finance including more than 13 years in the Bio-tech, life science and medical device industries. He has been in executive positions for several US public companies including their world-wide subsidiaries. Mr. Weinberg is a Certified Public Accountant since 1979 and holds an MBA from Bar Ilan University (1984) and a B.A. in Economics and Accounting from Tel Aviv University (1977).
Mr. David E. Price, Esq.
Mr. David E. Price is our Secretary and corporate attorney, a native
Washingtonian & has lived both in America and Israel & is fluent in several languages. David brings a dynamic and varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as a Congressional Aide in the US Congress, and General Counsel to
consultants at the World Bank as well as the IDB, EX-IM and IMF in
Washington, DC. He left a large international firm to create his own niche solo practice in mergers & acquisitions and brings years of knowledge both general and specific in the international business and corporate.
Board of Advisors
Dr. Sigalit Ariely-Portnoy
Senior advisor in the field of regulation, validation and quality, Dr. Sigalit Ariely-Portnoy has over 17 years’ experience in the pharmaceutical industry. During this time, she has managed
pharmaceutical and chemical plants at Taro pharmaceutical industries as Operation Group Vice president and in Teva Pharmaceutical industries. she managed Teva's largest plant worldwide.
9
During her career, she led more than 50 inspections by the US FDA, EMEA, Israeli MOH, and others. Dr. Ariely-Portnoy received her B.Sc., M.Sc., and D.Sc. from the Technion Institute of Technology in Haifa, Israel, in the fields of Chemical Engineering and Biomedical Engineering.
Mr. Isaac Abravanel
Senior advisor in the field of operational and strategic planning, Mr. Isaac Abravanel joined Teva Pharmaceutical Industries Ltd as its Corporate Vice President of Human Resources in 2007. During 2009, Mr. Abravanel was appointed as Teva’s Chief Integration Officer, and as such led the post-merger integration processes of Teva’s large acquisitions in recent years. In 2013 Mr. Abravanel was appointed as Group Executive Vice President of Teva Corporate in Israel and Global Community Alliances of Teva Pharmaceutical Industries Ltd. Mr. Abravanel holds a B.A and an M.A. in Political Science from Haifa University and is a Graduate of the National Security College.
